PHA’s PH Care Centers (PHCC) Program Accredits Five New Centers

2019-04-04T19:08:22+00:00April 4th, 2019|

The Pulmonary Hypertension Association’s (PHA’s) PH Care Centers (PHCC) Program recently accredited five new centers in support of its commitment to promoting quality care practices through PH center accreditation. Interest in PHA’s continuous quality improvement initiative remains high as PH programs seek accreditation as Centers of Comprehensive Care (CCC) and Regional Clinical Programs (RCP).

Generic Treprostinil Injection Launched for Intravenous Use

2019-04-04T18:19:34+00:00April 4th, 2019|

Generic treprostinil, the pulmonary arterial hypertension--targeted therapy currently sold as Remodulin®, is now available for individuals using the medication delivered intravenously. Generic treprostinil injection is approved by the U.S. Food and Drug Administration for both intravenous and subcutaneous use. However, generic treprostinil for subcutaneous use is not available at this time due to the

Second Generic Tadalafil Product Announced

2019-03-07T18:53:09+00:00March 7th, 2019|

Questions to Consider When Choosing Between Brand and Generic Therapy Teva Pharmaceutical Industries recently announced the launch of ALYQ ™ (tadalafil), a generic version of the drug Adcirca®. Mylan launched the first generic tadalafil in August. How an individual with pulmonary hypertension (PH) is impacted by the availability of generic therapy may depend on

Expert Panel Updates PAH Therapy Guidelines

2019-02-21T21:44:57+00:00February 21st, 2019|

Updated guidelines for pulmonary arterial hypertension (PAH) were recently completed by a panel of experts from the Pulmonary Hypertension Association, American Thoracic Society and the American Heart Association and published in the CHEST Journal. The panel, which included several PHA members and a patient representative, looked at 300 recent studies to complete the update

YouTube Videos Frequently Contain Misinformation on Idiopathic Pulmonary Fibrosis

2019-02-21T21:44:11+00:00February 21st, 2019|

Researchers and health care providers know that patients with rare diseases frequently rely on the internet for information on their condition, how it is diagnosed, how it is treated and how to live with a new condition. YouTube is frequently consulted, especially when tasks are being learned, such as mixing medications. But patient-directed

PHA’s Online Advances in Pulmonary Hypertension Examines Barriers in New PH Therapies

2019-01-31T20:19:28+00:00January 31st, 2019|

The latest issue of Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension Association (PHA) — a free quarterly publication directed by an editorial board of renowned pulmonary hypertension (PH) experts — includes an article by Brian Graham, M.D., Peter Fernandes, M. Pharm., and Sue Gu, M.D., that explores the barriers and solutions to

PHA Releases Updated Associated Condition Brochures

2019-01-24T22:04:34+00:00January 24th, 2019|

The Pulmonary Hypertension Association (PHA) updated and redesigned its PH& brochures, a series of 13 educational pamphlets that discuss the relationship of pulmonary hypertension (PH) and other conditions or diseases known to be related to PH. The series includes PH&: Congenital heart disease Chronic obstructive pulmonary disease Chronic thromboembolic disease Hereditary hemorrhagic telangiectasia HIV

Cardiovascular Institute of North Colorado Receives PHA’s PHCC Accreditation

2019-01-03T22:08:43+00:00January 3rd, 2019|

The Pulmonary Hypertension Association’s (PHA’s) Pulmonary Hypertension Care Centers (PHCC) program granted Regional Clinical Program (RCP) accreditation to the Cardiovascular Institute of North Colorado in December. PHA launched the PHCC accreditation program in 2014 to improve the quality of care and outcomes for people with pulmonary hypertension (PH). Nationwide, PHCCs provide treatment for more

WSPH Report Explores Importance of Patient Perspectives in PH

2019-01-03T22:09:49+00:00January 3rd, 2019|

In early 2018, a task force on the patient’s perspective was created at the sixth World Symposium on Pulmonary Hypertension (WSPH). This task force reviewed the role of patient associations such as the Pulmonary Hypertension Association (PHA) in supporting individuals with PH, examined how clinical teams can improve care and looked at improved access to

PH with COPD: Is Sildenafil an Effective Treatment Option?

2018-10-26T20:46:19+00:00October 26th, 2018|

by Phyllis Hanlon, Contributing Writer All of the 14 targeted therapies for pulmonary hypertension (PH) are approved for use in patients with World Health Organization (WHO) Group 1 PH (pulmonary arterial hypertension, or PAH), with one therapy also approved for use in patients with inoperable or recurrent WHO Group 4 PH (chronic thromboembolic pulmonary hypertension,